Prevalence of linezolid resistance in Streptococcus pneumoniae isolates: a systematic review and meta-analysis.
Mohsen HeidaryShirin DashtbinArezoo AsadiParisa AsadollahiAli KhatibMohammad Amin EbrahimiZahra GhanbariAtieh DarbandiRoya GhanavatiReza PakzadPublished in: Future microbiology (2024)
Aim: This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniae isolates reported over the past 10 years. Material & methods: An electronic search was conducted for the following keywords: (( Streptococcus pneumoniae [title/abstract]) OR ( Pneumococcus [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result: Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniae isolates ranged from 0% to 4.86%. Discussion: Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.
Keyphrases
- end stage renal disease
- risk factors
- randomized controlled trial
- methicillin resistant staphylococcus aureus
- genetic diversity
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- clinical trial
- systematic review
- staphylococcus aureus
- study protocol
- combination therapy
- replacement therapy